Stockreport

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call [Yahoo! Finance]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement data, during its first quarter 2026 ea [Read more]